Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Bria

Showing results (281-290 of 377) with videos related to

Pageof 38
Sort By:
Lung Cancer (Amsterdam, Netherlands)|March 31, 2009
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancerEmilio Bria, Michele Milella, Isabella Sperduti, et al.
Frontiers in Oncology|September 12, 2025
Low fT3/fT4 ratio as a proxy for muscle wasting in patients with advanced non-small cell lung cancer treated with pembrolizumabSerena Eccher, Marco Sposito, Ilaria Trestini, et al.
Cancer Genetics|February 19, 2017
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitorsMatteo Brunelli, Albino Eccher, Luca Cima, et al.
Journal of Cancer Research and Clinical Oncology|July 30, 2013
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinomaEleonora Brunello, Giuseppe Bogina, Emilio Bria, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trialAntonio Santo, Sara Pilotto, Domenico Galetta, et al.
Scientific Reports|January 23, 2023
Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, et al.
Therapeutic Advances in Medical Oncology|March 20, 2023
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapyGiovanna Garufi, Luisa Carbognin, Isabella Sperduti, et al.
The Oncologist|June 8, 2021
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority StudyLuigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, et al.
BMC Cancer|August 23, 2022
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 studyLuigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, et al.
The Journal of Pathology|November 23, 2016
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2DMichele Simbolo, Andrea Mafficini, Katarzyna O Sikora, et al.
Pageof 38

Showing results (281-290 of 377) with videos related to

Sort By:
Pageof 38
Lung Cancer (Amsterdam, Netherlands)|March 31, 2009
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancerEmilio Bria, Michele Milella, Isabella Sperduti, et al.
Frontiers in Oncology|September 12, 2025
Low fT3/fT4 ratio as a proxy for muscle wasting in patients with advanced non-small cell lung cancer treated with pembrolizumabSerena Eccher, Marco Sposito, Ilaria Trestini, et al.
Cancer Genetics|February 19, 2017
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitorsMatteo Brunelli, Albino Eccher, Luca Cima, et al.
Journal of Cancer Research and Clinical Oncology|July 30, 2013
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinomaEleonora Brunello, Giuseppe Bogina, Emilio Bria, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trialAntonio Santo, Sara Pilotto, Domenico Galetta, et al.
Scientific Reports|January 23, 2023
Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, et al.
Therapeutic Advances in Medical Oncology|March 20, 2023
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapyGiovanna Garufi, Luisa Carbognin, Isabella Sperduti, et al.
The Oncologist|June 8, 2021
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority StudyLuigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, et al.
BMC Cancer|August 23, 2022
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 studyLuigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, et al.
The Journal of Pathology|November 23, 2016
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2DMichele Simbolo, Andrea Mafficini, Katarzyna O Sikora, et al.
Pageof 38